Genomic analyses identify key molecules and significant signaling pathways in AZIN1 regulated prostate cancer cells

Tingxiang Chang, Hanming Gu^{*}, James Liu¹

¹SHU-UTS SILC School, Shanghai University, Shanghai, China

^{*}Corresponding author: Hanming Gu, SHU-UTS SILC School, Shanghai University, Shanghai, China

laygmp@gmail.com

Abstract

Antizyme inhibitor 1 (AZIN1) is a critical target in prostate cancer, which regulates the adenosine-to-inosine (A to I) RNA editing during the cancer progression. However, the potential signaling pathways and functions remain unknown. Here, our objective is to figure out the functional molecules and signaling pathways by analyzing the RNA-seq data. The GSE189379 was produced by the Illumina HiSeq 2000 (Homo sapiens). The KEGG and GO analyses showed that focal adhesion and proteoglycans are the mainly affected processes in prostate cancer with the loss of AZIN1. Moreover, we identified ten key molecules including FN1, HRAS, CCND1, RAD51, PCNA, TYMS, CASP3, RRM2, BIRC5, and CCNE2. Therefore, this study provides novel knowledge of AZIN1 mediated prostate cancer.

Introduction

Prostate cancer is the second most common cancer in men worldwide, and the incidence has elevated over ten years¹. Prostate cancer is not common under the age of 40, but the incidence is inclined with age². Studies showed environmental factors are critical for the development of prostate cancer¹. Environmental factors include the high intake of saturated fat and low dietary selenium, vitamin E, and vitamin D³. Reports showed that less than 5% of prostate cancer is hereditary, and the major reason for prostate cancer is caused by genetic mutational events¹. Deficient tumor-suppressive genes such as p53 and p73 appear to be the main cause for the development of prostate cancers⁴. However, the molecular mechanism of prostate cancer is still unclear. Antizyme inhibitor 1 (AZIN1) plays an important role in the polyamine biosynthetic pathway, which is a potential target for cancers⁵. AZIN1 was first found in the liver as an antizyme inhibitor (AZI), which contains two isoforms and involves tumorigenesis and aggressive behaviors⁶. AZIN1 gene is related to the survival and accelerated distant metastases in breast cancers, and the expression of AZIN1 is highly expressed in stomach, lung, and prostate cancers⁷. Overexpression of AZIN1 promotes tumor growth by maintaining polyamine homeostasis and cell proliferation⁸. Moreover, A to I RNA editing of AZIN contributes to cancer through regulating the polyamine⁵.

In this study, we explored the effects of AZIN1 on prostate cancer by using the RNA-seq data. We identified several DEGs and significant pathways through the KEGG and GO. We also construct the gene enrichment map and protein-protein interaction (PPI) network to study the relationships among the DEGs. These DEGs and biological processes will provide guidance on the treatment of prostate cancers.

Methods

Data resources

Gene dataset GSE189379 was downloaded from the GEO database. The data was produced by the Illumina HiSeq 2000 (Homo sapiens) (KU Leuven, Herestraat 49, Leuven, Belgium). The analyzed dataset includes 3 of controls and 3 of AZIN1 siRNA treated PC3 cells.

Data acquisition and processing

The data were organized and conducted by R package as previously described⁹⁻¹². We used a classical t-test to identify DEGs with $P < 0.05$ and fold change ≥ 1.5 as being statistically significant.

The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) KEGG and GO analyses were conducted by the R package (ClusterProfiler) and Reactome. $P < 0.05$ was considered statistically significant.

Protein-protein interaction (PPI) networks

The Molecular Complex Detection (MCODE) was used to create the PPI networks. The significant modules were produced from constructed PPI networks. The pathway analyses were performed by using Reactome (<https://reactome.org/>), and $P < 0.05$ was considered significant.

Results

Identification of DEGs in prostate cancer cells with deficient AZIN1

To determine the impact of AZIN1 on prostate cancer cells, we analyzed the RNA-seq data from the PC3 cells (prostate cells) with the knockout of AZIN1. A total of 1172 genes were identified with the threshold of $P < 0.05$. The up-and-down-regulated genes were shown by the heatmap and volcano plot (Figure 1). The top ten DEGs were selected in Table 1.

Enrichment analysis of DEGs by KEGG and GO analyses

To further figure out the mechanism of AZIN1 regulated cancer cells, we performed the KEGG and GO analyses (Figure 2). We identified the top ten KEGG signaling pathways including “Focal adhesion”, “Proteoglycans in cancer”, “Gastric cancer”, “Hepatocellular carcinoma”, “Cell cycle”, “Small cell lung cancer”, “Cellular senescence”, “Colorectal cancer”, “Prostate cancer”, and “Pancreatic cancer”. We also identified the top ten biological processes of GO including “Reproductive structure development”, “Reproductive system development”, “cell–substrate adhesion”, “DNA replication”, “sex differentiation”, “cell–matrix adhesion”, “gonad development”, “DNA–dependent DNA replication”, “male sex differentiation”, and “regulation of cell–matrix adhesion”. We identified the top ten cellular components of GO including “collagen–containing extracellular matrix”, “focal adhesion”, “cell–substrate junction”, “endoplasmic reticulum lumen”, “basement membrane”, “protein kinase complex”, “serine/threonine protein kinase complex”, “cyclin–dependent protein kinase holoenzyme complex”, “DNA replication preinitiation complex”, and “laminin complex”. We identified the top ten molecular functions of GO including “phosphoric ester hydrolase activity”, “small GTPase binding”, “GTPase binding”, “extracellular matrix structural constituent”, “phosphoprotein phosphatase activity”, “protein tyrosine phosphatase activity”, “cyclin–dependent protein serine/threonine kinase regulator activity”, “2–oxoglutarate–dependent dioxygenase activity”, “single–stranded DNA helicase activity”, and “1–phosphatidylinositol binding”.

PPI networks in prostate cancer cells with deficient AZIN1

To determine the relationship among the DEGs, we constructed the PPI networks by using the Cytoscape software (combine score > 0.4). Table 2 showed the top ten

interactive molecules with the highest degree scores. The top two modules were indicated in Figure 3. We further explored the mechanisms with Reactome map (Figure 4) and identified the top ten significant processes including “G1/S-Specific Transcription”, “Mitotic G1 phase and G1/S transition”, “G1/S Transition”, “NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux”, “NR1H2 and NR1H3-mediated signaling”, “Downstream signaling of activated FGFR1”, “Crosslinking of collagen fibrils”, “Assembly of collagen fibrils and other multimeric structures”, “Extracellular matrix organization”, and “PI-3K cascade:FGFR1” (Supplemental Table S1).

Discussion

AZIN1 is one of the most frequently occurring A-to-I RNA alterations in cancers and the overexpression of AZIN1 is associated with aggressive tumors and elevated ornithine decarboxylase and polyamines accumulation⁷. However, the molecular function of AZIN1 in prostate cancer remains unexplored.

Our study showed that the deficient AZIN1 in prostate cancer cells mainly affects the focal adhesion and proteoglycans processes. The study by Sheila Figel et al found that focal adhesion kinase is highly expressed in prostate cancer, which enhances the growth, survival, migration, metastasis of prostate tumors¹³. Thomas R Johnson et al also found focal adhesion kinase regulates the aggressive phenotype of prostate cancer cells¹⁴. Proteoglycans regulate cell signaling, adhesion, growth, and apoptosis, and the change of proteoglycans is observed in prostate cancers. Proteoglycans may become a tumor regulator through mediating the sonic hedgehog signaling. Moreover, changes in tumors can alter proteoglycan contents and structure to change their functions¹⁵.

By analyzing the Reactome map and PPI network, we identified the top ten interactive molecules that may involve the process of AZIN1 affected prostate cancers. The study by Dibash K Das et al showed that overexpression of FN1 is positively correlate with aggressive prostate cancer¹⁶. Clinton L Cario et al found that HRAS is a driver gene in the prostate cancer patients by using the machine learning methods¹⁷. G protein-coupled receptors (GPCRs) promote cells to respond to several stimuli through generation of second messengers, which in turn regulate a variety of processes such as

cell survival, proliferation, migration, and differentiation¹⁸⁻²⁸. As a key GTPase, HRAS was found to be involved in controlling the GPCR/cAMP signaling pathways, thereby mediating the cancer cells²⁹. Mingming Wang et al found the microRNA-4873-3p inhibits the progression of prostate cancer by targeting CCND1³⁰. Maria Nowacka-Zawisza et al proved that the RAD51 polymorphisms is closely related to the high risk of prostate cancer³¹. Huajun Zhao et al found the tyrosine phosphorylation of PCNA is a critical prostate cancer target³². Circadian clocks regulate numerous downstream genes and signaling pathways³³⁻⁴³. Most of genes indicate the rhythm during the day and night. Interestingly, the oscillation of PCNA was observed during the light and dark cycles, which may affect the proliferation of tumor cells⁴⁴. Christoph Burdelski et al found that the increased thymidylate synthase is related to aggressive tumor features in prostate cancer⁴⁵. As a key apoptosis gene, the CASP3 is upregulated in prostate cancer cell lines⁴⁶. Ying Z Mazzu et al found the RRM2 is increased in prostate cancer, which is a novel mechanism of poor-prognosis⁴⁷. Daixing Hu et al found the gene BIRC5 can be used to construct the prognostic model of prostate cancers⁴⁸. Zhong Wu et al found the cyclin E2 is a PTEN-regulated gene that is related to human prostate cancer metastasis⁴⁹.

In conclusion, our study found a strong relationship between AZIN1 and prostate cancer. The focal adhesion and proteoglycans are the major affected processes during the development of prostate cancer. Our study provides valuable insights for the treatment of prostate cancer.

Author Contributions

Tingxiang Chang: Methodology and Writing. Hanming Gu, James Liu: Conceptualization, Writing- Reviewing and Editing.

Funding

This work was not supported by any funding.

Declarations of interest

There is no conflict of interest to declare.

Figure 1. Heatmap and volcano plot in prostate cancer cells with deficient AZIN1

(A) Heatmap of significant DEGs in prostate cancer cells with deficient AZIN1. Significant DEGs ($P < 0.05$) were used to create the heatmap.

(B) Volcano plot for DEGs in prostate cancer cells with deficient AZIN1. The most significantly changed genes are highlighted by grey dots.

Figure 2. KEGG and GO analyses of DEGs in prostate cancer cells with deficient AZIN1

(A) KEGG analysis, (B) Biological processes, (C) Cellular components, (D) Molecular functions.

Figure 3. The PPI network analyses of DEGs in prostate cancer cells with deficient AZIN1

The top two clusters were constructed by MCODE according to the DEGs.

Figure 4. Reactome map representation of the significant biological processes in prostate cancer cells with deficient AZIN1

Table 1

Entrez gene	Gene symbol	Fold-change	Regulation
Top 10 down-regulated DEGs			
100750247	HIF1A-AS2	-2.376383392	Down
26121	RP11-314A20.2	-1.85953844	Down
27006	FGF22	-1.780925245	Down
84848	MIR503HG	-1.626864453	Down
81578	COL21A1	-1.541031361	Down
728888	NPIP11	-1.27400942	Down
114904	C1QTNF6	-1.235179154	Down
53354	PANK1	-1.140399494	Down
5010	CLDN11	-1.111857974	Down
283373	ANKRD52	-1.109250355	Down
Top 10 up-regulated DEGs			
51582	AZIN1	3.417660764	up
5918	RARRES1	2.2422406	up
284348	LYPD5	2.136706624	up
64386	MMP25	1.957904013	up
100507012	BMP1B-AS1	1.691060182	up
11144	DMC1	1.66058871	up
23591	FAM215A	1.51673144	up
79400	NOX5	1.386794453	up
125965	COX6B2	1.323880415	up
4060	LUM	1.307668372	up

Table 2. Top ten genes demonstrated by connectivity degree in the PPI network

Gene symbol	Gene title	Degree
FN1	Fibronectin 1	53
HRAS	Hras Proto-Oncogene, Gtpase	48
CCND1	Cyclin D1	43
RAD51	RAD51 Recombinase	33
PCNA	Proliferating Cell Nuclear Antigen	32
TYMS	Thymidylate Synthetase	31
CASP3	Caspase 3	30
RRM2	Ribonucleotide Reductase Regulatory Subunit M2	29
BIRC5	Baculoviral IAP Repeat Containing 5	27
CCNE2	Cyclin E2	27

References

- [1] Rawla P: Epidemiology of Prostate Cancer. *World J Oncol* 2019, 10:63-89.
- [2] Stangelberger A, Waldert M, Djavan B: Prostate cancer in elderly men. *Rev Urol* 2008, 10:111-9.
- [3] Statovci D, Aguilera M, MacSharry J, Melgar S: The Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces. *Front Immunol* 2017, 8:838.
- [4] Bieging KT, Mello SS, Attardi LD: Unravelling mechanisms of p53-mediated tumour suppression. *Nat Rev Cancer* 2014, 14:359-70.
- [5] Qiu S, Liu J, Xing F: Antizyme inhibitor 1: a potential carcinogenic molecule. *Cancer Sci* 2017, 108:163-9.
- [6] Olsen RR, Zetter BR: Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. *Mol Cancer Res* 2011, 9:1285-93.
- [7] Shigeyasu K, Okugawa Y, Toden S, Miyoshi J, Toiyama Y, Nagasaka T, Takahashi N, Kusunoki M, Takayama T, Yamada Y, Fujiwara T, Chen L, Goel A: AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer. *JCI Insight* 2018, 3.
- [8] Omura N, Mizuma M, MacGregor A, Hong SM, Ayars M, Almaro JA, Borges M, Kanda M, Li A, Vincent A, Maitra A, Goggins M: Overexpression of ankyrin1 promotes pancreatic cancer cell growth. *Oncotarget* 2016, 7:34977-87.
- [9] Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012, 16:284-7.
- [10] Hanming G: Identification of the difference of neutrophils in different locations in RA patients. *Research Square* 2021.
- [11] Gu H, Yuan G: Identification of potential biomarkers and inhibitors for SARS-CoV-2 infection. *medRxiv* 2020:2020.09.15.20195487.
- [12] Zhang M, Wang J, Gu H: Identification of biological processes and signaling pathways in the stretched nucleus pulposus cells. *bioRxiv* 2021:2021.11.23.469730.
- [13] Figel S, Gelman IH: Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. *Anticancer Agents Med Chem* 2011, 11:607-16.
- [14] Johnson TR, Khandrika L, Kumar B, Venezia S, Koul S, Chandhoke R, Maroni P, Donohue R, Meacham RB, Koul HK: Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer. *Mol Cancer Res* 2008, 6:1639-48.
- [15] Edwards IJ: Proteoglycans in prostate cancer. *Nat Rev Urol* 2012, 9:196-206.
- [16] Das DK, Ogunwobi OO: A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. *RNA Dis* 2017, 4.
- [17] Cario CL, Chen E, Leong L, Emami NC, Lopez K, Tenggara I, Simko JP, Friedlander TW, Li PS, Paris PL, Carroll PR, Witte JS: A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. *BMC Cancer* 2020, 20:820.
- [18] Stewart A, Fisher RA: Introduction: G Protein-coupled Receptors and RGS Proteins. *Prog Mol Biol Transl Sci* 2015, 133:1-11.
- [19] Yuan G, Yang S, Yang S: Macrophage RGS12 contributes to osteoarthritis pathogenesis through enhancing the ubiquitination. *Genes & Diseases* 2021.
- [20] Yuan G, Yang S, Yang S, Ng A, Oursler MJ: RGS12 is a critical proinflammatory factor in the pathogenesis of inflammatory arthritis via acting in Cox2-RGS12-NF kappa B pathway activation loop. *J Bone Miner Res: WILEY* 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2019. pp. 147-.
- [21] Fu C, Yuan G, Yang ST, Zhang D, Yang S: RGS12 Represses Oral Cancer via the Phosphorylation and SUMOylation of PTEN. *J Dent Res* 2020:22034520972095.

- [22] Yuan G, Huang Y, Yang ST, Ng A, Yang S: RGS12 inhibits the progression and metastasis of multiple myeloma by driving M1 macrophage polarization and activation in the bone marrow microenvironment. *Cancer Commun (Lond)* 2022, 42:60-4.
- [23] Xie K, Martemyanov KA: Control of striatal signaling by g protein regulators. *Front Neuroanat* 2011, 5:49.
- [24] Yuan G, Yang S, Ng A, Fu C, Oursler MJ, Xing L, Yang S: RGS12 Is a Novel Critical NF-kappaB Activator in Inflammatory Arthritis. *iScience* 2020, 23:101172.
- [25] Yuan G, Fu C, Yang ST, Yuh DY, Hajishengallis G, Yang S: RGS12 Drives Macrophage Activation and Osteoclastogenesis in Periodontitis. *J Dent Res* 2021:220345211045303.
- [26] Rosenbaum DM, Rasmussen SG, Kobilka BK: The structure and function of G-protein-coupled receptors. *Nature* 2009, 459:356-63.
- [27] Yuan G, Yang S, Liu M, Yang S: RGS12 is required for the maintenance of mitochondrial function during skeletal development. *Cell Discov* 2020, 6:59.
- [28] Yuan G, Yang S, Gautam M, Luo W, Yang S: Macrophage regulator of G-protein signaling 12 contributes to inflammatory pain hypersensitivity. *Ann Transl Med* 2021, 9:448.
- [29] Semesta KM, Tian R, Kampmann M, von Zastrow M, Tsvetanova NG: A high-throughput CRISPR interference screen for dissecting functional regulators of GPCR/cAMP signaling. *PLoS Genet* 2020, 16:e1009103.
- [30] Wang M, Yu W, Gao J, Ma W, Frentsch M, Thiel A, Liu M, Rahman N, Qin Z, Li X: MicroRNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. *J Cell Physiol* 2020, 235:1588-600.
- [31] Nowacka-Zawisza M, Raszkiewicz A, Kwasiborski T, Forma E, Brys M, Rozanski W, Krajewska WM: RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer. *J Oncol* 2019, 2019:2976373.
- [32] Zhao H, Lo YH, Ma L, Waltz SE, Gray JK, Hung MC, Wang SC: Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. *Mol Cancer Ther* 2011, 10:29-36.
- [33] Reppert SM, Weaver DR: Coordination of circadian timing in mammals. *Nature* 2002, 418:935-41.
- [34] Yuan G, Hua B, Cai T, Xu L, Li E, Huang Y, Sun N, Yan Z, Lu C, Qian R: Clock mediates liver senescence by controlling ER stress. *Aging* 2017, 9:2647-65.
- [35] Zhu Z, Hua B, Xu L, Yuan G, Li E, Li X, Sun N, Yan Z, Lu C, Qian R: CLOCK promotes 3T3-L1 cell proliferation via Wnt signaling. *IUBMB Life* 2016, 68:557-68.
- [36] Fan XF, Wang XR, Yuan GS, Wu DH, Hu LG, Xue F, Gong YS: [Effect of safflower injection on endoplasmic reticulum stress-induced apoptosts in rats with hypoxic pulmonary hypertension]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi* 2012, 28:561-7.
- [37] Xu L, Cheng Q, Hua B, Cai T, Lin J, Yuan G, Yan Z, Li X, Sun N, Lu C, Qian R: Circadian gene Clock regulates mitochondrial morphology and functions by posttranscriptional way. *bioRxiv* 2018:365452.
- [38] Yuan G, Hua B, Yang Y, Xu L, Cai T, Sun N, Yan Z, Lu C, Qian R: The Circadian Gene Clock Regulates Bone Formation Via PDIA3. *J Bone Miner Res* 2017, 32:861-71.
- [39] Zhu Z, Xu L, Cai T, Yuan G, Sun N, Lu C, Qian R: Clock represses preadipocytes adipogenesis via GILZ. *J Cell Physiol* 2018, 233:6028-40.
- [40] Mao SZ, Fan XF, Xue F, Chen R, Chen XY, Yuan GS, Hu LG, Liu SF, Gong YS: Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation. *Pulm Pharmacol Ther* 2014, 27:1-9.
- [41] Yuan G, Xu L, Cai T, Hua B, Sun N, Yan Z, Lu C, Qian R: Clock mutant promotes osteoarthritis by inhibiting the acetylation of NFkappaB. *Osteoarthritis Cartilage* 2019, 27:922-31.
- [42] Zhu Z, Hua B, Shang Z, Yuan G, Xu L, Li E, Li X, Sun N, Yan Z, Qian R, Lu C: Altered Clock and Lipid Metabolism-Related Genes in Atherosclerotic Mice Kept with Abnormal Lighting Condition. *Biomed Res Int* 2016, 2016:5438589.

- [43] Cai T, Hua B, Luo D, Xu L, Cheng Q, Yuan G, Yan Z, Sun N, Hua L, Lu C: The circadian protein CLOCK regulates cell metabolism via the mitochondrial carrier SLC25A10. *Biochim Biophys Acta Mol Cell Res* 2019, 1866:1310-21.
- [44] Song H, Wang D, De Jesus Perez F, Xie R, Liu Z, Chen CC, Yu M, Yuan L, Fernald RD, Zhao S: Rhythmic expressed clock regulates the transcription of proliferating cellular nuclear antigen in teleost retina. *Exp Eye Res* 2017, 160:21-30.
- [45] Burdelski C, Strauss C, Tsourlakis MC, Kluth M, Hube-Magg C, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Krech T, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S: Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. *Oncotarget* 2015, 6:8377-87.
- [46] Salemi M, Condorelli RA, La Vignera S, Barone N, Ridolfo F, Giuffrida MC, Vicari E, Calogero AE: PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines. *Hum Cell* 2014, 27:172-5.
- [47] Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW: A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). *Clin Cancer Res* 2019, 25:4480-92.
- [48] Hu D, Jiang L, Luo S, Zhao X, Hu H, Zhao G, Tang W: Development of an autophagy-related gene expression signature for prognosis prediction in prostate cancer patients. *J Transl Med* 2020, 18:160.
- [49] Wu Z, Cho H, Hampton GM, Theodorescu D: Cdc6 and cyclin E2 are PTEN-regulated genes associated with human prostate cancer metastasis. *Neoplasia* 2009, 11:66-76.